Clinical Trial Update: Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 trial update of sorafenib with or without VT-122 in hepatocellular carcinoma. The current status of the study is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• VT-122

Snippet

Sponsor: Vicus Therapeutics | Conditions: HCC | Phase 2 | Status: UNKNOWN